To evaluate the clinical effectiveness of urapidil combined with MS and nifedipine in gestational hypertension (GH). A retrospective article design was employed to collect clinical data from 200 patients with GH. The sample size was estimated using PASS 15.0 software based on the primary outcome measure (systolic blood pressure reduction), with α = 0.05, β = 0.2, and effect size = 0.8, ensuring a minimum total sample size of 180 cases (expanded to 200 cases to account for potential data loss). Patients were divided into two groups based on prior remedy regimens: the experimental group (EG, 125 patients, treated with urapidil combined with MS and nifedipine) and the control group (CG, 75 patients, treated with MS and nifedipine). Patients’ blood pressure (BP), hemodynamic indicators, serum inflammatory factors, renal function indicators, adverse pregnancy outcomes, and clinical efficacy before and following remedy were collected. In the EG, the systolic and diastolic blood pressure (SBP, DBP) were visiblely lower compared with the control group, and the hemodynamic, inflammatory factors, and renal function indicators following remedy were significantly improved. The total remedy efficacy in the EG was 92.8%, significantly higher than the 86.67% in the CG. Additionally, the incidence of adverse pregnancy outcomes in the EG (premature birth, miscarriage, postpartum hemorrhage, neonatal asphyxia) was visiblely lower compared with the control group (P < 0.05). The intervention plan of urapidil combined with MS and nifedipine has certain clinical advantages in the management of GH, effectively reducing BP, improving hemodynamics, alleviating inflammatory responses, and reducing adverse pregnancy outcomes.
Tang et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: